Events

Investors



Corporate Profile

Rigel Pharmaceuticals, Inc. is a biotechnology company dedicated to discovering, developing and providing novel, small molecule drugs that significantly improve the lives of patients with immune and hematological disorders, cancer and rare diseases.

Recent News

More »
DateTitle 
05/01/18Rigel Announces First Quarter 2018 Financial Results and Provides Company Update
Rigel Expected to Launch TAVALISSE™ (fostamatinib disodium hexahydrate) in the U.S. in late May 2018 Conference Call and Webcast Today at 5:00PM Eastern Time SOUTH SAN FRANCISCO, Calif., May 1, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL), today reported financial results for the first quarter ended March 31, 2018. TAVALISSE Launch Update During the conference call today, Rigel will discuss the TAVALISSE market access plans, including the wholesale acquisition cost ... 
Printer Friendly Version
04/30/18TAVALISSE™ (fostamatinib disodium hexahydrate) Phase 3 Data Published in the American Journal of Hematology Describes Pivotal Data and Overall Response Rate Versus Placebo
SOUTH SAN FRANCISCO, Calif., April 30, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that the American Journal of Hematology has published positive results from the Fostamatinib in Thrombocytopenia (FIT) Phase 3 clinical program of TAVALISSE™ (fostamatinib disodium hexahydrate) for the treatment of adults with chronic immune thrombocytopenia (ITP). The study, "Fostamatinib for the Treatment of Adult Persistent and Chronic Immune Thrombocytopenia: Results of Two P... 
Printer Friendly Version
04/24/18Rigel Announces Conference Call and Webcast to Report First Quarter 2018 Financial Results
SOUTH SAN FRANCISCO, Calif., April 24, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its first quarter 2018 financial results after market close on Tuesday, May 1, 2018.  Rigel senior management will follow the announcement with a live conference call and webcast at 5:00pm Eastern Time (2:00pm Pacific Time) to discuss the financial results and provide a company update. Participants can access the live conference call by dialing 855-892-1489... 
Printer Friendly Version

Upcoming Events

More »

There are currently no events scheduled.

Stock Quote

RIGL (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$3.91
Change (%) - 0.04 (1.01%)
Volume765,809
Data as of 05/25/18 4:00 p.m. ET   Refresh quote

Stock Chart

Stock chart for: RIGL.O.  Currently trading at $3.91 with a 52 week high of $4.71 and a 52 week low of $2.14.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources

E-mail Alerts

Sign up to receive e-mail alerts whenever Rigel Pharmaceuticals Inc. posts new information to the site. Just enter your e-mail address and click Submit.